-
Innovent Announces ORIENT-31, a Phase 3 Study of Sintilimab in Patients with EGFR-Mutated Nonsquamous Non-Small Cell Lung Cancer with Prior EGFR-TKI Treatment, Has Met Primary Endpoint
18 Oct 2021 00:25 GMT
… registrational or pivotal clinical trials.
In China, sintilimab … gemcitabine and platinum chemotherapy, for the first-line treatment … #39;s National Reimbursement Drug List (NRDL) in … high-quality innovative medicines for the treatment of cancer, autoimmune …
-
Global Stretch Marks Treatment Market to be Driven by increasing prevalence of obesity among the population in the Forecast Period of 2021-2026
12 Oct 2021 06:34 GMT
… 'Global Stretch Marks Treatment Market Size, Share, Price … marks do not necessitate medical intervention. They are … Surgical Devices Market:
Global Gemcitabine HCL Market:
Global … industry verticals which include Pharmaceuticals, Food and Beverage, …
-
Can a new drug make pancreatic cells responsive to chemotherapy?
04 Oct 2021 00:42 GMT
… to every anti-cancer treatment. Targeting TAK-1 could … with the anti-cancer drugs gemcitabine, oxaliplatin and SN-38 … of a classic chemotherapeutic drug, gemcitabine, that would have been … bedside, conducting a clinical trial that could demonstrate the …
-
FDA Accepts Libtayo (cemiplimab-rwlc) for Priority Review for Advanced Cervical Cancer
28 Sep 2021 12:04 GMT
… or gemcitabine). The primary endpoint for the trial was … Libtayo. Call your doctor for medical advice about side effects … into medicine has led to nine FDA-approved treatments and … the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron …
-
Amplia Therapeutics shifts from pre-clinical to drug development with two potent candidates for cancer and fibrotic diseases treatment
21 Sep 2021 06:42 GMT
… included leading cancer and medicinal chemistry researchers at Australia … this trial, Amplia is preparing for Phase 2 trials of … the US Food and Drug Administration (FDA) for use in … in combination with gemcitabine/Abraxane® for the treatment of cancer, …
-
Merck announces positive results from phase 3 KEYNOTE─355 trial of Keytruda in combo with chemotherapy to treat mTNBC whose tumors expressed PD─L1
21 Sep 2021 06:42 GMT
… pivotal phase 3 KEYNOTE-355 trial investigating Keytruda, Merck’s anti … -paclitaxel or gemcitabine/carboplatin) for the first-line treatment of patients … , director, Breast Oncology and Clinical Trials Education, University of California San …
-
HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the Treatment of Advanced Neuroendocrine Carcinoma in China
21 Sep 2021 00:49 GMT
… from the Phase II trial were disclosed for the … granted drug registration approval by the National Medical Products … S. Food and Drug Administration ("FDA”) New Drug Application (“NDA”) … cisplatin and gemcitabine as the first-line treatment for patients …
-
International Pharmaceutical News: OBS Group Completes 6th Acquisition in Pakistan
17 Sep 2021 17:00 GMT
… planning the introduction of new drugs to complement its existing … in the general medicines category, and Paclitaxel and Gemcitabine in the … network in the biotech/pharmaceutical industry. The group connects pharmaceutical and medical device companies …
-
Innovent Releases Interim Analysis Results of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma in the Phase 3 ORIENT-15 Study at ESMO Congress 2021
18 Sep 2021 00:10 GMT
… based on platinum drugs for unresectable locally advanced … registrational or pivotal clinical trials.
In China, sintilimab … gemcitabine and platinum chemotherapy, for the first-line treatment … high quality innovative medicines for the treatment of cancer, …
-
Amplia Therapeutics to conduct Phase 2 trial for Focal Adhesion Kinase inhibitor AMP945 in first line pancreatic cancer patients
16 Sep 2021 07:33 GMT
… therapy for pancreatic cancer.
The pharmaceutical company plans to initiate patient … treatment.
The Phase 2 clinical trial will add AMP945 to chemotherapy with gemcitabine … at the Garvan Institute of Medical Research, Sydney, where it has …
About
© 1995-2021